
FDA Fully Approves TIVDAK® for Treating Recurrent or Metastatic Cervical Cancer
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) have received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab…












